Duchossois Family Institute, Knapp Center for Biomedical Discovery (KCBD), Room 4214
Chicago, Illinois, 60637, United States
NCT Number: NCT07700368
The goal of this clinical trial is to learn whether dietary monosodium glutamate (MSG), a common food flavor enhancer, increases the blood level of a gut-microbiome-derived compound called imidazole propionate (ImP) in healthy adult volunteers. ImP is a compound made by gut bacteria from the amino acid histidine, and higher blood levels have been linked to problems with blood-sugar control. The main questions this trial aims to answer are:
Does taking MSG together with L-histidine increase blood ImP levels compared with taking a salt (sodium chloride) placebo together with L-histidine? How do blood ImP levels change over time in response to MSG and L-histidine taken together?
Researchers will compare a 7-day period of L-histidine plus MSG against a 7-day period of L-histidine plus sodium chloride (a salt placebo with matching sodium content) to see whether MSG changes blood ImP levels. Each participant completes both periods in random order and serves as their own comparison.
Participants will:
Take L-histidine capsules twice daily (morning and evening with meals) during two separate 7-day periods.
Dissolve either MSG powder or salt powder in water and drink it twice daily during each period, with the two periods separated by a 7-day break (washout).
Give a fasting blood sample at the start of the study and on day 7 of each period.
Optionally provide a stool sample at the end of each period. Complete a daily treatment diary and a follow-up phone call after the final sample.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Chicago, Illinois, 60637, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
USP-grade L-histidine, 4 g/day, taken as capsules divided into 2 g in the morning and 2 g in the evening with meals, during each 7-day treatment period. Administered in both treatment periods for all participants.
Food-grade monosodium glutamate, 3 g/day, provided as identical-appearing single-dose powder sachets divided into 1.5 g in the morning and 1.5 g in the evening, each dissolved in approximately 240 mL
USP-grade sodium chloride, 940 mg/day, provided as identical-appearing single-dose powder sachets divided into 470 mg in the morning and 470 mg in the evening, each dissolved in approximately 240 mL of water and taken with meals during the placebo treatment period. The sodium content is matched to that of the 3 g/day MSG dose to isolate the effect of glutamate.
Time frame: Day 7 of each treatment period
Blood imidazole propionate concentration measured by liquid chromatography-mass spectrometry (LC-MS) from the blood sample collected on day 7 of each 7-day treatment period. The outcome is the within-participant difference between the day-7 concentration following the L-histidine + MSG period and the day-7 concentration following the L-histidine + NaCl period.
Contact information is provided by the study sponsor or research team.
University of Chicago
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07717710
Behavior, Healthy Adult
Vancouver, British Columbia, Canada
View Trial DetailsNCT07716319
Athlete, Exercise Training
Madison, Wisconsin, United States
View Trial DetailsNCT07711587
Glucose Metabolism Disorders, Healthy Adult
View Trial DetailsNCT07711340
Behavior, Exercise
Stanford, California, United States
View Trial Details